Mangala Srinivas, theme Nanomedicine, showed in Advanced Functional Materials that nano‐particles (radius 100 nm), are suitable for long‐term in vivo ultrasound in combination with 19F MRI and fluorescence.Publication: link.
Ultrasound is the most commonly used clinical imaging modality. However, in applications requiring cell‐labeling, the large size and short active lifetime of ultrasound contrast agents limit their longitudinal use. Here, 100 nm radius, clinically applicable, polymeric nanoparticles containing a liquid perfluorocarbon, which enhance ultrasound contrast during repeated ultrasound imaging over the course of at least 48 h, are described. The perfluorocarbon enables monitoring the nanoparticles with quantitative 19F magnetic resonance imaging, making these particles effective multimodal imaging agents. Unlike typical core–shell perfluorocarbon‐based ultrasound contrast agents, these nanoparticles have an atypical fractal internal structure. The nonvaporizing highly hydrophobic perfluorocarbon forms multiple cores within the polymeric matrix and is, surprisingly, hydrated with water, as determined from small‐angle neutron scattering and nuclear magnetic resonance spectroscopy. Finally, the nanoparticles are used to image therapeutic dendritic cells with ultrasound in vivo, as well as with 19F MRI and fluorescence imaging, demonstrating their potential for long‐term in vivo multimodal imaging.
Related news items
Step-up approach vs open necrosectomy for necrotizing pancreatitis18 April 2019
Another publication of the successful Dutch collaborative group on pancreatitis research with substantial contribution from Radboudumc researchers, Harry van Goor and Kees van Laarhoven.read more
Prophylactic antibiotics reduce hospitalisations and cost in head and neck cancer patients18 April 2019
In European journal of cancer Janneke Ham and colleagues showed that prophylactic antibiotics in locally advanced head and neck cancer patients treated with chemoradiotherapy did not reduce the incidence of (aspiration) pneumonias, but did reduce hospitalisations and tended to be cost-effective.read more
Nontuberculous mycobacteria and fungal co-infections Bonnie and Clyde?18 April 2019
In The European respiratory journal Jakko van Ingen and Sanne Zweijpfenning showed that 40% of patients diagnosed with nontuberculous mycobacterial pulmonary disease also meet diagnostic criteria for chronic pulmonary aspergillosis.read more
ESCMID award for groundbreaking studies on NTM disease18 April 2019
Jakko van Ingen received the ESCMID Young Investigator Award for his groundbreaking work on nontuberculous mycobacterial disease.read more
EU funded project BIOMAP led by Ellen van den Bogaard12 April 2019
Ellen van den Bogaard, theme Inflammatory diseases, leads the research on the experimental validation and functional analysis of identified biomarkers by using advanced organotypic skin models and receives a grant of €258,000.read more